Survivorship – Chronic Lymphocytic Leukemia (CLL)



[1] Consider use of Vanderbilt's ABCDE's approach to cardiovascular health
[2] Labs may be monitored by primary care provider (PCP)

Department of Clinical Effectiveness V1
Approved by The Executive Committee of the Medical Staff on 11/15/2023

Survivorship – Chronic Lymphocytic Leukemia (CLL)



[1] See Physical Activity, Nutrition, and Tobacco Cessation Treatment algorithms; ongoing reassessment of lifestyle risks should be a part of routine clinical practice
[2] Includes breast, cervical (if appropriate), colorectal, lung, pancreatic, prostate, and skin cancer screening
[3] Based on Centers for Disease Control and Prevention (CDC) guidelines
[4] Can be administered > 6 months after anti-CD20 monoclonal antibody treatment

Department of Clinical Effectiveness V1
Approved by The Executive Committee of the Medical Staff on 11/15/2023

APPENDIX A: Pneumococcal Vaccine[1] Schedules for Adults

Prior Vaccines	Recommendations
None or Unknown	1 dose of PCV20 **or** 1 dose of PCV15 followed by 1 dose of PPSV23 at least 8 weeks after PCV15
PPSV23 only	1 dose of PCV20 **or** PCV15 at least ≥ 1 year after the last pneumococcal vaccine
PCV13 only	1 dose of PCV20 **or** PPSV23 at least 8 weeks after PCV13, with second dose of PPSV23 given at least ≥ 5 years
PCV13 and 1 dose of PPSV23	1 dose of PCV20 at least ≥ 5 years after the last pneumococcal vaccine **or** 1 dose of PPSV23 at least 8 weeks after PCV13 and at least ≥ 5 years after the first dose of PPSV23
PCV13 and 2 doses of PPSV23[2]	The decision to administer 1 dose of PCV20 at least ≥ 5 years of last pneumococcal vaccine is a shared clinical decision between the patient and the provider

PCV13 = pneumococcal 13-valent conjugate vaccine
PCV15 = pneumococcal 15-valent conjugate vaccine
PCV20 = pneumococcal 20-valent conjugate vaccine
PPSV23 = pneumococcal polysaccharide 23-valent vaccine

[1] Based on Centers for Disease Control and Prevention (CDC) guidelines
[2] For adults ages ≥ 65 years of age, who received 1 dose of PCV13 at any age and all recommended doses of PPSV23 (including 1 dose of PPSV23 at ≥ 65 years of age)

SUGGESTED READINGS

Ammenheuser, M. (2017, February 21). *The ABCDEs of caring for the heart during cancer treatment - and beyond*. Vanderbilt Health. https://my.vanderbilthealth.com/heart-damage-chemotherapy-radiation/

Archibald, W. J., Meacham, P. J., Williams, A. L. M., Baran, A. M., Victor, A. I., Barr, P. M., . . . Zent, C. S. (2018). Management of melanoma in patients with chronic lymphocytic leukemia. *Leukemia Research, 71*, 43-46. https://doi.org/10.1016/j.leukres.2018.07.003

Centers for Disease Control and Prevention. (2023). *Pneumococcal Vaccination*. Retrieved from https://www.cdc.gov/vaccines/vpd/pneumo/index.html

Centers for Disease Control and Prevention. (2023). *Recommended immunization schedule for adults aged 19 years or older, United States, 2023.* Retrieved from https://www.cdc.gov/vaccines/schedules/hcp/imz/adult.html

Chavez, J. C., Kharfan-Dabaja, M. A., Kim, J., Yue, B., Dalia, S., Pinilla-Ibarz, J., . . . Locke, F. L. (2014). Genomic aberrations deletion 11q and deletion 17p independently predict for worse progression-free and overall survival after allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia. *Leukemia Research, 38*(10), 1165-1172. https://doi.org/10.1016/j.leukres.2014.04.006

Davis, A. S., Viera, A. J., & Mead, M. D. (2014). Leukemia: An Overview for Primary Care. *American Family Physician, 89*(9), 731-738.

Desikan, S. P., Venugopal, S., & Ferrajoli, A. (2022). BTK inhibitor selection for chronic lymphocytic leukemia: Which drug for which patient? *Expert Review of Hematology, 15*(5), 403-409. https://doi.org/10.1080/17474086.2022.2074393

Else, M., Cocks, K., Crofts, S., Wade, R., Richards, S. M., Catovsky, D., & Smith, A. G. (2012). Quality of life in chronic lymphocytic leukemia: 5-year results from the multicenter randomized LRF CLL4 trial. *Leukemia & Lymphoma, 53*(7), 1289-1298. https://doi.org/10.3109/10428194.2011.649479

Falchi, L., Keating, M. J., Marom, E. M., Truong, M. T., Schlette, E. J., Sargent, R. L., . . . Ferrajoli, A. (2014). Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia. *Blood, 123*(18), 2783-2790. https://doi.org/10.1182/blood-2013-11-536169

Falchi, L., Keating, M. J., Wang, X., Coombs, C. C., Lanasa, M. C., Strom, S., . . . Ferrajoli, A. (2013). Clinical characteristics, response to therapy, and survival of African American patients diagnosed with chronic lymphocytic leukemia: Joint experience of the MD Anderson Cancer Center and Duke University Medical Center. *Cancer, 119*(17), 3177-3185. https://doi.org/10.1002/cncr.28030

Gordon, M. J., & Ferrajoli, A. (2022). Unusual complications in the management of chronic lymphocytic leukemia. *American Journal of Hematology, 97*(S2), S26-S34. https://doi.org/10.1002/ajh.26585

Gordon, M. J., Jones, J. E., George, B., Peterson, C., Burger, J. A., Jain, N., . . . Ferrajoli, A. (2023). Long-term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicity. *Cancer.* Advance online publication. https://doi.org/10.1002/cncr.34787

Iskierka-Jazdzewska, E., & Robak, T. (2020). Minimizing and managing treatment-associated complications in patients with chronic lymphocytic leukemia. *Expert Review of Hematology, 13*(1), 39-53. https://doi.org/10.1080/17474086.2020.1696185

Continued on next page

SUGGESTED READINGS - continued

Larsson, K., Mattsson, M., Ebrahim, F., Glimelius, I., & Hoglund, M. (2020). High prevalence and incidence of cardiovascular disease in chronic lymphocytic leukaemia: A nationwide population-based study. *British Journal of Haematology, 190*(4), e245-e248. https://doi.org/10.1111/bjh.16859

Malhotra, P., Hogan, W. J., Litzow, M. R., Elliott, M. A., Gastineau, D. A., Ansell, S. M., . . . Tefferi, A. (2008). Long-term outcome of allogeneic stem cell transplantation in chronic lymphocytic leukemia: Analysis after a minimum follow-up of 5 years. *Leukemia & Lymphoma, 49*(9), 1724-1730. https://doi.org/10.1080/10428190802263535

National Comprehensive Cancer Network. (2023). *Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma* (NCCN Guideline Version 2.2023). https://www.nccn.org/professionals/physician_gls/pdf/cll.pdf

Pashos, C. L., Flowers, C. R., Kay, N. E., Weiss, M., Lamanna, N., Farber, C., . . . Khan, Z. M. (2013). Association of health-related quality of life with gender in patients with B-cell chronic lymphocytic leukemia. *Supportive Care in Cancer, 21*(10), 2853-2860. https://doi.org/10.1007/s00520-013-1854-z

Rivera, D., & Ferrajoli, A. (2022). Managing the risk of infection in chronic lymphocytic leukemia in the era of new therapies. *Current Oncology Reports, 24*(8), 1003-1014. https://doi.org/10.1007/s11912-022-01261-9

Royle, J. A., Baade, P. D., Joske, D., Girschik, J., & Fritschi, L. (2011). Second cancer incidence and cancer mortality among chronic lymphocytic leukaemia patients: A population-based study. *British Journal of Cancer, 105*(7), 1076-1081. https://doi.org/10.1038/bjc.2011.313

Shen, Y., Coyle, L., Kerridge, I., Stevenson, W., Arthur, C., McKinlay, N., . . . Mulligan, S. P. (2022). Second primary malignancies in chronic lymphocytic leukaemia: Skin, solid organ, haematological and Richter's syndrome. *British Society for Haematology, 3*(1), 129-138. https://doi.org/10.1002/jha2.366

Tsimberidou, A.-M., Wen, S., McLaughlin, P., O'Brien, S., Wierda, W. G., Lerner, S., . . . Keating, M. J. (2009). Other Malignancies in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. *Journal of Clinical Oncology, 27*(6), 904-910. https://doi.org/10.1200/JCO.2008.17.5398

van den Broek, E. C., Oerlemans, S., Nijziel, M. R., Posthuma, E. F. M., Coebergh, J. W. W., & van de Poll-Franse, L. V. (2015). Impact of active surveillance, chlorambucil, and other therapy on health-related quality of life in patients with CLL/SLL in the Netherlands. *Annals of Hematology, 94*(1), 45-56. https://doi.org/10.1007/s00277-014-2161-6

DEVELOPMENT CREDITS

This survivorship algorithm is based on majority expert opinion of the Leukemia Survivorship workgroup at the University of Texas MD Anderson Cancer Center. It was developed using a multidisciplinary approach that included input from the following:

Core Development Team Leads

Alessandra Ferrajoli, MD (Leukemia)

Workgroup Members

Ella J. Ariza-Heredia, MD (Infectious Diseases)
Jovan Borjan, PharmD (Pharmacy Clinical Programs)
Jackie Broadway-Duren, PhD, DNP, APRN, FNP-BC (Leukemia)
Wendy Garcia, BS♦
Katherine Gilmore, MHP (Cancer Survivorship)
Thoa Kazantsev, MSN, RN, OCN♦
Jill Miller, PA-C (Leukemia)
Alma Rodriguez, MD (Lymphoma/Myeloma)
Whittney Thoman, MS, ACSM-CEP, ACSM-EIM-III, ACSM-CET (Cancer Survivorship)
William Wierda, MD, PhD (Leukemia)

♦ Clinical Effectiveness Development Team